CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Rain Therapeutics Inc. - RAIN CFD

    1.05
    0.94%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.05
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Rain Oncology Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 1.06
    Open* 1.04
    1-Year Change* -86.73%
    Day's Range* 1.04 - 1.05
    52 wk Range 0.82-14.48
    Average Volume (10 days) 145.67K
    Average Volume (3 months) 3.75M
    Market Cap 38.92M
    P/E Ratio -100.00K
    Shares Outstanding 36.38M
    Revenue N/A
    EPS -2.07
    Dividend (Yield %) N/A
    Beta -100.00K
    Next Earnings Date Mar 7, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Nov 27, 2023 1.06 -0.02 -1.85% 1.08 1.08 1.06
    Nov 24, 2023 1.07 0.05 4.90% 1.02 1.07 1.02
    Nov 22, 2023 1.04 -0.01 -0.95% 1.05 1.05 1.03
    Nov 21, 2023 1.05 -0.01 -0.94% 1.06 1.06 1.03
    Nov 20, 2023 1.06 0.00 0.00% 1.06 1.07 1.03
    Nov 17, 2023 1.07 0.03 2.88% 1.04 1.07 1.00
    Nov 16, 2023 1.02 -0.07 -6.42% 1.09 1.09 1.02
    Nov 15, 2023 1.09 0.00 0.00% 1.09 1.10 1.08
    Nov 14, 2023 1.07 -0.04 -3.60% 1.11 1.12 1.06
    Nov 13, 2023 1.08 0.05 4.85% 1.03 1.11 1.02
    Nov 10, 2023 1.05 0.07 7.14% 0.98 1.08 0.98
    Nov 9, 2023 1.00 -0.05 -4.76% 1.05 1.09 0.97
    Nov 8, 2023 1.08 0.04 3.85% 1.04 1.10 1.04
    Nov 7, 2023 1.09 0.01 0.93% 1.08 1.09 1.07
    Nov 6, 2023 1.09 0.03 2.83% 1.06 1.10 1.06
    Nov 3, 2023 1.10 0.02 1.85% 1.08 1.10 1.06
    Nov 2, 2023 1.08 0.04 3.85% 1.04 1.10 1.04
    Nov 1, 2023 1.06 0.03 2.91% 1.03 1.07 1.02
    Oct 31, 2023 1.05 0.03 2.94% 1.02 1.05 1.02
    Oct 30, 2023 1.04 -0.02 -1.89% 1.06 1.06 1.03

    Rain Therapeutics Inc. Events

    Time (UTC) Country Event
    Thursday, March 7, 2024

    Time (UTC)

    21:00

    Country

    US

    Event

    Q4 2023 Rain Oncology Inc Earnings Release
    Q4 2023 Rain Oncology Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019
    Total revenue 0 0 0 0
    Total Operating Expense 77.136 51.512 18.958 10.828
    Selling/General/Admin. Expenses, Total 15.736 10.739 3.591 3.538
    Research & Development 61.4 40.773 10.2 7.29
    Unusual Expense (Income) 5.167 0
    Operating Income -77.136 -51.512 -18.958 -10.828
    Interest Income (Expense), Net Non-Operating 1.415 0.119 -0.103 0.177
    Other, Net -0.001 -2.022 -0.251
    Net Income Before Taxes -75.721 -51.394 -21.083 -10.902
    Net Income After Taxes -75.724 -51.392 -21.083 -10.902
    Net Income Before Extra. Items -75.724 -51.392 -21.083 -10.902
    Net Income -75.724 -51.392 -21.083 -10.902
    Income Available to Common Excl. Extra. Items -75.724 -51.394 -21.083 -10.902
    Income Available to Common Incl. Extra. Items -75.724 -51.394 -21.083 -10.902
    Diluted Net Income -75.724 -51.394 -21.083 -10.902
    Diluted Weighted Average Shares 27.9855 19.4058 25.9692 25.9692
    Diluted EPS Excluding Extraordinary Items -2.70584 -2.64838 -0.81185 -0.41981
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -2.70584 -2.64838 -0.61288 -0.41981
    Total Adjustments to Net Income -0.002
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 23.231 21.743 23.557 18.411 17.718
    Selling/General/Admin. Expenses, Total 5.414 5.066 4.479 3.901 3.461
    Research & Development 14.98 16.677 19.078 14.51 14.257
    Operating Income -23.231 -21.743 -23.557 -18.411 -17.718
    Interest Income (Expense), Net Non-Operating 1.167 1.259 0.882 0.37 0.107
    Net Income Before Taxes -22.064 -20.484 -22.675 -18.041 -17.611
    Net Income After Taxes -22.064 -20.484 -22.678 -18.041 -17.611
    Net Income Before Extra. Items -22.064 -20.484 -22.678 -18.041 -17.611
    Net Income -22.064 -20.484 -22.678 -18.041 -17.611
    Income Available to Common Excl. Extra. Items -22.064 -20.484 -22.678 -18.041 -17.611
    Income Available to Common Incl. Extra. Items -22.064 -20.484 -22.678 -18.041 -17.611
    Diluted Net Income -22.064 -20.484 -22.678 -18.041 -17.611
    Diluted Weighted Average Shares 36.3633 36.3399 32.3354 26.5646 26.5295
    Diluted EPS Excluding Extraordinary Items -0.60677 -0.56368 -0.70134 -0.67914 -0.66383
    Dividends per Share - Common Stock Primary Issue 0 0 0 0 0
    Diluted Normalized EPS -0.52875 -0.56368 -0.70134 -0.67914 -0.66383
    Other, Net 0
    Unusual Expense (Income) 2.837
    • Annual
    • Quarterly
    2022 2021 2020 2019
    Total Current Assets 133.628 146.146 59.525 6.274
    Cash and Short Term Investments 130.454 140.218 58.863 5.794
    Cash & Equivalents 61.955 24.78 58.863 5.794
    Prepaid Expenses 2.432 5.252 0.53 0.37
    Other Current Assets, Total 0.742 0.676 0.132 0.11
    Total Assets 135.18 147.14 61.08 7.395
    Property/Plant/Equipment, Total - Net 0.351 0.551 0.546 0.692
    Property/Plant/Equipment, Total - Gross 0.587 0.707 0.631 0.725
    Accumulated Depreciation, Total -0.236 -0.156 -0.085 -0.033
    Note Receivable - Long Term 0.052 0.298 0.549 0.354
    Other Long Term Assets, Total 1.149 0.145 0.46 0.075
    Total Current Liabilities 21.966 16.315 3.419 1.224
    Accounts Payable 7.146 6.112 0.816 0.261
    Accrued Expenses 14.82 10.203 1.076 0.684
    Notes Payable/Short Term Debt 0 0 0 0
    Other Current Liabilities, Total 1.527 0.279
    Total Liabilities 22.144 16.636 3.8 4.496
    Total Long Term Debt 0 0 0 2.751
    Long Term Debt 0 2.751
    Other Liabilities, Total 0.178 0.321 0.381 0.521
    Total Equity 113.036 130.504 57.28 2.899
    Redeemable Preferred Stock 0 0 95.024 20.147
    Common Stock 0.037 0.027 0.004 0.003
    Additional Paid-In Capital 278.853 220.53 1.149 0.236
    Retained Earnings (Accumulated Deficit) -165.688 -89.964 -38.57 -17.487
    Total Liabilities & Shareholders’ Equity 135.18 147.14 61.08 7.395
    Total Common Shares Outstanding 36.2903 26.4758 25.9692 25.9692
    Preferred Stock - Non Redeemable, Net -0.327
    Short Term Investments 68.499 115.438
    Other Equity, Total -0.166 -0.089
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 80.816 90.993 112.975 133.628 93.745
    Cash and Short Term Investments 77.32 86.29 109.77 130.454 90.708
    Cash & Equivalents 37.312 40.076 44.1 61.955 39.834
    Prepaid Expenses 2.665 3.969 2.502 2.432 2.615
    Total Assets 82.06 91.723 114.178 135.18 94.635
    Property/Plant/Equipment, Total - Net 1.064 0.55 0.299 0.351 0.394
    Other Long Term Assets, Total 0.18 0.18 0.851 1.149 0.443
    Total Current Liabilities 14.477 18.331 19.48 21.966 13.013
    Accounts Payable 8.973 5.801 7.421 7.146 4.084
    Accrued Expenses 5.504 12.53 12.059 14.82 8.929
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 14.541 18.434 19.621 22.144 13.226
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 0.064 0.103 0.141 0.178 0.213
    Total Equity 67.519 73.289 94.557 113.036 81.409
    Redeemable Preferred Stock 0 0 0 0
    Preferred Stock - Non Redeemable, Net
    Common Stock 0.037 0.037 0.037 0.037 0.027
    Additional Paid-In Capital 282.816 281.588 280.739 278.853 224.694
    Retained Earnings (Accumulated Deficit) -215.27 -208.236 -186.172 -165.688 -143.01
    Total Liabilities & Shareholders’ Equity 82.06 91.723 114.178 135.18 94.635
    Total Common Shares Outstanding 36.3757 36.3757 36.3632 36.2903 26.5648
    Short Term Investments 40.008 46.214 65.67 68.499 50.874
    Other Equity, Total -0.064 -0.1 -0.047 -0.166 -0.302
    Note Receivable - Long Term 0 0.053 0.052 0.053
    Other Current Assets, Total 0.831 0.734 0.703 0.742 0.422
    Property/Plant/Equipment, Total - Gross 1.489 0.821 0.553 0.587 0.612
    Accumulated Depreciation, Total -0.425 -0.271 -0.254 -0.236 -0.218
    • Annual
    • Quarterly
    2022 2021 2020 2019
    Net income/Starting Line -75.724 -51.394 -21.083 -10.902
    Cash From Operating Activities -63.199 -37.463 -11.231 -11.182
    Cash From Operating Activities 0.08 0.071 0.052 0.028
    Non-Cash Items 3.515 8.672 8.191 0.519
    Changes in Working Capital 8.93 5.188 1.609 -0.827
    Cash From Investing Activities 47.194 -118.235 -5.191 -0.144
    Capital Expenditures -0.008 -0.128 -0.024 -0.144
    Other Investing Cash Flow Items, Total 47.202 -118.107 -5.167 0
    Cash From Financing Activities 53.18 121.615 69.491 2.5
    Financing Cash Flow Items -3.467 -11.872 -0.166 0
    Issuance (Retirement) of Stock, Net 56.647 133.487 63.222 0
    Issuance (Retirement) of Debt, Net 0 6.435 2.5
    Net Change in Cash 37.175 -34.083 53.069 -8.826
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -20.484 -75.724 -53.046 -35.005 -17.394
    Cash From Operating Activities -21.839 -63.199 -49.905 -34.542 -17.11
    Cash From Operating Activities 0.018 0.08 0.062 0.044 0.022
    Non-Cash Items 0.998 3.515 2.556 2.709 1.275
    Changes in Working Capital -2.371 8.93 0.523 -2.29 -1.013
    Cash From Investing Activities 3.518 47.194 64.386 52.76 13.436
    Capital Expenditures -0.008 0 0 0
    Cash From Financing Activities 0.466 53.18 0.573 0.411 0.399
    Financing Cash Flow Items -0.089 -3.467 0
    Net Change in Cash -17.855 37.175 15.054 18.629 -3.275
    Other Investing Cash Flow Items, Total 3.518 47.202 64.386 52.76 13.436
    Issuance (Retirement) of Stock, Net 0.555 56.647 0.573 0.411 0.399
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Tang Capital Management, LLC Hedge Fund 14.5921 4024486 284145 2023-10-13 MED
    BVF Partners L.P. Hedge Fund 12.7873 3526729 0 2023-08-10 LOW
    Vellanki (Avanish) Individual Investor 9.2491 2550910 -59618 2023-03-01
    Samsara BioCapital, LLC Venture Capital 7.3769 2034552 -226100 2023-06-30 LOW
    Boxer Capital, L.L.C. Hedge Fund 4.1777 1152212 0 2023-06-30 LOW
    Berger (Franklin Milan) Individual Investor 3.6447 1005207 0 2023-03-01 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 3.3666 928499 855288 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.282 905171 24081 2023-06-30 LOW
    Polen Capital Management, LLC Investment Advisor/Hedge Fund 2.6088 719513 0 2023-08-31 LOW
    Acadian Asset Management LLC Investment Advisor/Hedge Fund 2.3907 659349 656571 2023-06-30 MED
    Millennium Management LLC Hedge Fund 2.1796 601143 556303 2023-06-30 HIGH
    Doebele (Robert) Individual Investor 1.7289 476827 0 2023-03-01 LOW
    Acuitas Investments LLC Investment Advisor/Hedge Fund 1.4839 409256 409256 2023-09-30 HIGH
    Two Sigma Investments, LP Hedge Fund 1.3657 376670 298668 2023-06-30 HIGH
    Western Standard, LLC Hedge Fund 1.2585 347089 347089 2023-06-30 HIGH
    Ghost Tree Capital, LLC Hedge Fund 1.1784 325000 75000 2023-06-30 HIGH
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.1728 323471 161578 2023-06-30 LOW
    Goldman Sachs & Company, Inc. Research Firm 0.8652 238616 153534 2023-06-30 MED
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.8143 224571 169508 2023-06-30 LOW
    Exchange Traded Concepts, LLC Investment Advisor 0.4616 127306 14494 2023-09-30 HIGH

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Rain Therapeutics Inc. Company profile

    About Rain Therapeutics Inc

    Rain Therapeutics Inc. (Rain) is a clinical-stage precision oncology company. The Company is engaged in developing therapies that target oncogenic drivers. The Company's lead product candidate, RAIN-32 (milademetan) is a small molecule, oral inhibitor of mouse double minute 2 (MDM2). It is being developed in patients with MDM2 amplified or overexpressed cancers. MDM2 inhibition is a treatment approach due to dose-limiting on-target hematologic toxicities. The initial development opportunity for RAIN-32 be in patients with MDM2-amplified tumors, beginning with well-differentiated/de-differentiated (WD/DD) liposarcoma (LPS) patients. Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. RAD inhibition leads to synthetic lethality in the DNA damage repair (DDR) pathway.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Rain Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased from $21.1M to $51.4M. Higher net loss reflects Research and development expense increase from $9.6M to $38.3M (expense), General and administrative expense increase from $3.3M to $10.1M (expense), Stock-based Compensation in R&D increase from $581K to $2.5M (expense).

    Industry: Biotechnology & Medical Research (NEC)

    8000 Jarvis Avenue
    Suite 204
    NEWARK
    CALIFORNIA 94560
    US

    Income Statement

    • Annual
    • Quarterly

    News

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    Gold Rises as Traders price-in Fed Rate Cuts

    Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.

    13:17, 20 November 2023
    Gold bars

    XAU/USD Latest: Gold advances as weaker data weighs on US yields

    Gold moves higher as softer economic data weighs on US yields and the dollar

    13:43, 17 November 2023

    People also watch

    US100

    16,015.50 Price
    +0.340% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Oil - Crude

    76.73 Price
    +2.120% 1D Chg, %
    Long position overnight fee -0.0187%
    Short position overnight fee -0.0032%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    BTC/USD

    37,934.90 Price
    +2.250% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Gold

    2,045.30 Price
    +1.530% 1D Chg, %
    Long position overnight fee -0.0192%
    Short position overnight fee 0.0110%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading